Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas

BACKGROUND: RAS is dysregulated in neurofibromatosis type 1 (NF1) related plexiform neurofibromas (PNs). The activity of tipifarnib, which blocks RAS signaling by inhibiting its farnesylation, was tested in children and young adults with NF1 and progressive PNs. METHODS: Patients aged 3–25 years wit...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Widemann, Brigitte C., Dombi, Eva, Gillespie, Andrea, Wolters, Pamela L., Belasco, Jean, Goldman, Stewart, Korf, Bruce R., Solomon, Jeffrey, Martin, Staci, Salzer, Wanda, Fox, Elizabeth, Patronas, Nicholas, Kieran, Mark W., Perentesis, John P., Reddy, Alyssa, Wright, John J., Kim, AeRang, Steinberg, Seth M., Balis, Frank M.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Oxford University Press 2014
Θέματα:
Clinical Investigations
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3984559/
https://ncbi.nlm.nih.gov/pubmed/24500418
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou004
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια